Status:
COMPLETED
A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).
Lead Sponsor:
Pfizer
Conditions:
ATTR-CM
Eligibility:
All Genders
50+ years
Brief Summary
This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical di...
Eligibility Criteria
Inclusion
- HF patients (defined as having ≥1 claim for HF or HF treatment) ≥50 years old with clinical diagnosis of ATTRwt-CM or non-amyloid HF ascertained by charts. Patients will be required to have ≥12 months of continuous activity in the EHR or claims prior to the Index Date.
Exclusion
- Patients with any of the following diagnoses:
- Light chain (AL) amyloidosis
- Intracranial hemorrhage
- Cerebral amyloid angiopathy
- End stage renal disease
- Blood cancer
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 14 2023
Estimated Enrollment :
558 Patients enrolled
Trial Details
Trial ID
NCT06029452
Start Date
September 1 2023
End Date
November 14 2023
Last Update
January 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10018